Bone Loss After Denosumab: Only Partial Protection with Zoledronate

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

Steven R. Cummings, Javier San Martín, Michael R. McClung et al. · New England Journal of Medicine · 2009 · 3.4K citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

Henry G. Bone, Michael A. Bolognese, Chui Kin Yuen et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 611 citations

Medicine, Endocrinology, Bone Metabolism +16

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

Paul D. Miller, Michael A. Bolognese, E. Michael Lewiecki et al. · Bone · 2008 · 574 citations

Medicine, Clinical Sciences, Endocrinology +17

Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

Nick Freemantle, Sacha Satram‐Hoang, En‐Tzu Tang et al. · Osteoporosis International · 2011 · 283 citations · Full text

Pharmacy, Pharmacotherapy, Pain Medicine +16

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

Socrates E. Papapoulos, Kurt Lippuner, Christian Roux et al. · Osteoporosis International · 2015 · 277 citations · Full text

Medicine, Endocrinology, Bone Metabolism +16